Presented at the 40th Annual EAU Congress, the ARANOTE study offered valuable post hoc insights into the significance of PSA response in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with darolutamide (DARO) plus androgen deprivation therapy (ADT).
The findings showed that 62.6% of patients receiving DARO achieved undetectable PSA levels (<0.2 ng/mL) three times more than the placebo arm. This response was strongly associated with improved outcomes, including significantly lower risks of radiological progression, PSA progression, and time to mCRPC. The correlation held across all baseline PSA subgroups, supporting undetectable PSA as a promising marker of long-term benefit.
Congratulations to Dr. Fred Saad, Dr. Haresh K.P., Dr. Neal Shore, Dr. Vjaters Elvire V., Dr. Olmos Dolores O., Dr. Littleton Nancy, Dr. Testa Ilaria, Dr. @Srinivasan S. Sriram, Dr. Verholen Frank, and Dr. Alberto Briganti for their contribution to this important clinical investigation.
